These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7741319)

  • 41. PGE1 treatment of severe skin ischemia in patients with peripheral arterial insufficiency--the effect on skin microcirculation.
    Fagrell B; Lundberg G; Olsson A; Ostergren J
    Vasa; 1986; 15(1):56-60. PubMed ID: 3962459
    [No Abstract]   [Full Text] [Related]  

  • 42. [Hemodynamic effects of intermittent intra-arterial infusion treatment with prostaglandin E1 in peripheral arterial occlusive disease].
    Ranke C; Creutzig A; Alexander K
    Med Klin (Munich); 1991 Jul; 86(7):349-52, 382. PubMed ID: 1921896
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Transcutaneous oxygen partial pressure and systolic malleolar artery pressure in patients with peripheral arterial occlusive disease. Longitudinal measurements over 14 days].
    Heidrich H; Lammersen T
    Med Klin (Munich); 1993 Oct; 88(10):564-7. PubMed ID: 8272016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
    Rudofsky G
    Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
    [No Abstract]   [Full Text] [Related]  

  • 45. [Long-term blood pressure measurements with i.v. prostaglandin E1 infusion].
    Heidrich H; Brodel C; Meuche C; Hellmann G; Ranft J
    Vasa Suppl; 1989; 27():46. PubMed ID: 2623542
    [No Abstract]   [Full Text] [Related]  

  • 46. Influence of diabetic neuropathy on skin microcirculation assessed by transcutaneous oxymetry.
    Caspary L; Abicht J; Creutzig A; Mitzkat HJ; Alexander K
    Vasa; 1995; 24(4):340-6. PubMed ID: 8533444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
    Balzer K; Rogatti W; Rüttgerodt K
    Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Vital capillary microscopic examination and transcutaneous pO2-measurements by intravenous prostaglandin E1 infusion].
    Heidrich H; Lammersen T
    Dtsch Med Wochenschr; 1985 Aug; 110(34):1283-5. PubMed ID: 4040847
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Variability of TcPO2-measurements at 37 degrees C and 44 degrees C in patients with claudication in consideration of provocation tests.
    Caspary L; Creutzig A; Alexander K
    Vasa; 1993; 22(2):129-36. PubMed ID: 8322501
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of cutaneous necrosis risk in peripheral arterial diseases].
    D'Eri A; Martini R; Cordova RM; Trevisan G; Andreozzi GM
    Minerva Cardioangiol; 2002 Jun; 50(3):239-44. PubMed ID: 12107403
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Spinal cord stimulation in critical limb ischemia of the lower extremities: our experience.
    Petrakis IE; Sciacca V
    J Neurosurg Sci; 1999 Dec; 43(4):285-93. PubMed ID: 10864391
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of prostaglandin E1 on muscular tissue-PO2 in patients with diabetic gangrene.
    Heinrich R; Krawzak HW; Strosche H
    Adv Exp Med Biol; 1989; 248():699-704. PubMed ID: 2506745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [O2 inhalation and lowering leg position as a provocation test for transcutaneous measurement of partial oxygen pressure (tcpO2) in advanced peripheral arterial occlusive disease].
    Scheffler A; Rieger H
    Vasa Suppl; 1991; 33():269-70. PubMed ID: 1788709
    [No Abstract]   [Full Text] [Related]  

  • 54. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
    Heidrich H
    Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are there predictors for the outcome of a PGE1 treatment in peripheral arterial disease with critical limb ischaemia?
    Heidrich H; Schmidt T; Fahrig C
    Vasa; 2005 May; 34(2):101-7. PubMed ID: 15968891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some haemorheological factors and transcutaneous PO2 in patients with a peripheral arterial occlusive disease after treatment with naftidrofuryl.
    Krupiński K; Bielawiec M; Szpak A; Płonowski A
    Mater Med Pol; 1994; 26(1):17-20. PubMed ID: 7857406
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Transcutaneous oxygen pressure (TcPO2): advantages and limitations].
    Got I
    Diabetes Metab; 1998 Sep; 24(4):379-84. PubMed ID: 9805653
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Importance of cutaneous postural reflex vasoconstriction in patients with atherosclerotic occlusive disease of the lower extremities.
    Vayssairat M; Tribout L; Gouny P; Gaitz JP; Baudot N; Cheynel C; Nussaume O
    Int Angiol; 1998 Mar; 17(1):53-7. PubMed ID: 9657249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictive value of transcutaneous oxygen pressure and amputation success by use of supine and elevation measurements.
    Bacharach JM; Rooke TW; Osmundson PJ; Gloviczki P
    J Vasc Surg; 1992 Mar; 15(3):558-63. PubMed ID: 1538514
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Value of measuring transcutaneous oxygen pressure in arterial disease of the legs].
    Becker F; Gabrielle F; Raoux MH; Brenot R; David M
    Ann Cardiol Angeiol (Paris); 1989 Oct; 38(8):465-72. PubMed ID: 2596817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.